Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy-Reference-Cited by-同舟云学术

Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy

Published:2011-05 Issue:5 Volume:27 Page:525-533
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Magenta L.¹,Dell-Kuster S.²,Richter W.O.³,Young J.²,Hasse B.⁴,Flepp M.⁵,Hirschel B.⁶,Vernazza P.⁷,Evison J.⁸,Cavassini M.⁹,Decosterd L.A.¹⁰,Bucher H.C.²,Bernasconi, and the Swiss HIV Cohor E.¹

Affiliation:

1. Division of Infectious Diseases, Hospital of Lugano, Lugano, Switzerland.

2. Basel Institute for Clinical Epidemiology, University Hospital of Basel, Basel, Switzerland.

3. Institute for Lipoprotein Metabolism, Munich, Germany.

4. Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Zurich, Switzerland.

5. Zentrum für Infektionskrankheiten, Klinik im Park, Zurich, Switzerland.

6. Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.

7. Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland.

8. Division of Infectious Diseases, University Hospital of Bern, Bern, Switzerland.

9. Division of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland.

10. Division of Clinical Pharmacology-Laboratory, University Hospital of Lausanne, Lausanne, Switzerland.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2010.0207

Reference43 articles.

1. Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

2. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors

3. Risk of Metabolic Abnormalities in Patients Infected with HIV Receiving Antiretroviral Therapy that Contains Lopinavir‐Ritonavir

4. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection

5. Lipid Profiles in HIV‐Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study;Current HIV Research;2019-12-04

2. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis;Diabetes/Metabolism Research and Reviews;2017-06-16

3. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study;Antiviral therapy;2016

4. Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: A systematic review and meta-analysis;International Journal of Cardiology;2015-11

5. Evolution of Framingham cardiovascular risk score in HIV-infected patients initiating EFV- and LPV/r-based HAART in a Latin American cohort;Journal of the International AIDS Society;2014-11